KR20050089803A - 새로운 용도의 덱스트란 설페이트 - Google Patents
새로운 용도의 덱스트란 설페이트 Download PDFInfo
- Publication number
- KR20050089803A KR20050089803A KR1020057009717A KR20057009717A KR20050089803A KR 20050089803 A KR20050089803 A KR 20050089803A KR 1020057009717 A KR1020057009717 A KR 1020057009717A KR 20057009717 A KR20057009717 A KR 20057009717A KR 20050089803 A KR20050089803 A KR 20050089803A
- Authority
- KR
- South Korea
- Prior art keywords
- dextran sulfate
- cell
- pharmaceutically acceptable
- ibmir
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Transplantation (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
LMW-DS없이배양된 API | LMW-DS (0.01mg/ml)로 배양된 API | LMW-DS (0.1mg/ml)로 배양된 API | LMW-DS (1 mg/ml)로 배양된 API | |
생존율(% IEQ) | 57.0±5.2 | 43.6±6.7 | 58.4±4.3 | 68.9±2.6 |
SGS 시험에서의 자극 지수 | 1.77±0.17 | 2.26±0.51 | 3.22±0.89 | 1.42±0.35 |
ADP/ATP 비율 | 0.11±0.03 | 0.08±0.03 | 0.10±0.03 | 0.11±0.01 |
인슐린/DNA 비율(pmol/㎍) | 79.0 ±11.4 | 66.1±5.8 | 69.1±9.6 | 71.6±7.4 |
실험 1 | 실험 2 | 실험 3 | 실험 4 | |
첨가제 없음 | 5.6 | 6.3 | 6.9 | 5.5 |
LMW-DS(0.01mg/ml) | >60 | >60 | >60 | >60 |
LMW-DS(0.1mg/ml) | >60 | >60 | >60 | >60 |
LMW-DS(0.01mg/ml) | 15.8 | 36.9 | 21.0 | 38.3 |
LMW-DS(0.1mg/ml) | >60 | >60 | >60 | >60 |
LMW-DS(0.01mg/ml) | 19.2 | 11.3 | ||
LMW-DS(0.1mg/ml) | 25.2 | 25.8 | ||
LMW-DS(0.01mg/ml) | 19.8 | 13.8 | ||
LMW-DS(0.1mg/ml) | 14.2 | 33.2 |
이식 부위 | 처리 | n | 각각의 이식 생존(일) | 평균 이식 생존(일) |
간 | 식염수 | 6 | 1,1,2,3,6,8 | 3.5±1.2* |
LMW-DS | 5 | 4,6,8,12,14 | 8.8±1.9* | |
신장피막하 | - | 5 | > 56(×5) | > 56* |
Claims (22)
- 즉각적 혈액-매개 염증 반응 (IBMIR)의 치료 약제의 제조를 위한 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 제 1항에 있어서, 상기 IBMIR은 상기 세포 이식물의 외부 수용체로의 이식을 수반하는, 혈액에 대한 세포 이식물의 노출에 의하여 유발되는 것을 특징으로 하는 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 이식된 세포 이식물의 형태학적 파괴의 치료 약제의 제조를 위한 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 제 3항에 있어서, 상기 세포 이식물의 형태학적 파괴는 즉각적 혈액-매개 염증 반응 (IBMIR)으로 인한 것임을 특징으로 하는 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 세포 이식물의 이식 거부의 치료 약제의 제조를 위한 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 제 5항에 있어서, 상기 세포 이식물의 이식 거부는 즉각적 혈액-매개 염증 반응 (IBMIR)으로 인한 것임을 특징으로 하는 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 제 2항 내지 6항 중 어느 한 항에 있어서, 상기 세포 이식물은 수용체 인체로 이식되는 것을 특징으로 하는 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 제 2항 내지 7항 중 어느 한 항에 있어서, 상기 세포 이식물은 다음 목록에서 선택되는 것을 특징으로 하는 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체:- 동종이계(allogeneic)의 세포 이식물; 또는- 이종의(xenogeneic) 세포 이식물.
- 제 2항 내지 8항 중 어느 한 항에 있어서, 상기 세포 이식물은 다음 목록에서 선택되는 것을 특징으로 하는 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체:각각의 세포;세포의 덩어리; 또는비-혈관 조직.
- 제 2항 내지 9항 중 어느 한 항에 있어서, 상기 세포 이식물은 랑게르한스섬인 것을 특징으로 하는 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 전술한 청구항 중 어느 한 항에 있어서, 상기 덱스트란 설페이트는 20,000 Da 미만, 바람직하게는 10,000 Da 미만의 분자량을 가지는 것을 특징으로 하는 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 전술한 청구항 중 어느 한 항에 있어서, 상기 덱스트란 설페이트는 10-25 %, 바람직하게는 15-20 %의 황 함량을 가지는 것을 특징으로 하는 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체.
- 즉각적 혈액-매개 염증 반응(IBMIR)의 치료가 필요한 환자에게 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체의 치료적 유효량을 투여하는 단계를 포함하는 즉각적 혈액-매개 염증 반응(IBMIR)의 치료 방법.
- 제 13항에 있어서, 상기 환자는 사람 환자이며, 상기 IBMIR은 상기 환자의 수용체 신체 내부로의 세포 이식물의 이식을 수반하는 외부 혈액에 대한 세포 이식물의 노출에 의해 유발되는 것을 특징으로 하는 즉각적 혈액-매개 염증 반응(IBMIR)의 치료 방법.
- 즉각적 혈액-매개 염증 반응의 치료가 필요한 환자에게 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체의 치료적 유효량을 투여하는 단계를 포함하는, 세포 이식물의 이식 거부의 치료 방법.
- 제 15항에 있어서, 상기 환자는 사람 환자이며, 상기 세포 이식물의 이식 거부는 즉각적 혈액-매개 염증 반응 (IBMIR)으로 인한 것임을 특징으로 하는, 세포 이식물의 이식 거부의 치료 방법.
- 이식된 세포 이식물의 형태학적 파괴의 치료가 필요한 환자에게 덱스트란 설페이트 또는 제약학적으로 수용가능한 이들의 유도체의 치료적 유효량을 투여하는 단계를 포함하는, 이식된 세포 이식물의 형태학적 파괴의 치료 방법.
- 제 17항에 있어서, 상기 환자는 사람 환자이며, 상기 세포 이식물의 형태학적 파괴는 즉각적 혈액-매개 염증 반응 (IBMIR)으로 인한 것임을 특징으로 하는, 이식된 세포 이식물의 형태학적 파괴의 치료 방법.
- 제 13항 내지 18항 중 어느 한 항에 있어서, 상기 덱스트란 설페이트의 치료적 유효량은 상기 환자의 혈액 중에 5 mg/ml 미만, 바람직하게는 0.01-1 mg/ml 미만, 더욱 바람직하게는 0.05-0.2 mg/ml 미만의 덱스트란 설페이트 농도로 결과되는 것을 특징으로 하는 치료 방법.
- 제 14항, 15항 또는 17항 중 어느 한 항에 있어서, 상기 덱스트란 설페이트는 상기 덱스트란 설페이트에 용해된 상기 세포 이식물을 주사함으로써 투여되는 것을 특징으로 하는 치료 방법.
- 제 13항 내지 20항 중 어느 한 항에 있어서, 상기 덱스트란 설페이트는 20,000 Da 미만, 바람직하게는 10,000 Da 미만의 분자량을 가지는 것을 특징으로 하는 치료 방법.
- 제 13항 내지 21항 중 어느 한 항에 있어서, 상기 덱스트란 설페이트는 10-25 %, 바람직하게는 15-20 %의 황 함량을 가지는 것을 특징으로 하는 치료 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203526A SE525461C3 (sv) | 2002-11-28 | 2002-11-28 | Ny användning av dextransulfat |
SE0203526-9 | 2002-11-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050089803A true KR20050089803A (ko) | 2005-09-08 |
KR100828807B1 KR100828807B1 (ko) | 2008-05-09 |
Family
ID=20289705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057009717A KR100828807B1 (ko) | 2002-11-28 | 2003-11-26 | 새로운 용도의 덱스트란 설페이트 |
Country Status (26)
Country | Link |
---|---|
US (5) | US8629123B2 (ko) |
EP (1) | EP1567171B1 (ko) |
JP (2) | JP4315908B2 (ko) |
KR (1) | KR100828807B1 (ko) |
CN (1) | CN1296051C (ko) |
AT (1) | ATE359798T1 (ko) |
AU (1) | AU2003302378B2 (ko) |
BR (1) | BRPI0316666B8 (ko) |
CA (1) | CA2507595C (ko) |
CY (1) | CY1106739T1 (ko) |
DE (1) | DE60313356T2 (ko) |
DK (1) | DK1567171T3 (ko) |
EA (1) | EA010409B1 (ko) |
ES (1) | ES2285270T3 (ko) |
HK (1) | HK1087042A1 (ko) |
HR (1) | HRP20050439B1 (ko) |
IL (1) | IL168626A (ko) |
IS (1) | IS2405B (ko) |
NO (1) | NO326946B1 (ko) |
NZ (1) | NZ540744A (ko) |
PL (1) | PL216067B1 (ko) |
PT (1) | PT1567171E (ko) |
SE (1) | SE525461C3 (ko) |
SI (1) | SI1567171T1 (ko) |
WO (1) | WO2004047848A1 (ko) |
ZA (1) | ZA200504111B (ko) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008046162A1 (en) * | 2006-10-20 | 2008-04-24 | The Australian National University | Inhibition of degradation of extracellular matrix |
US20110008343A1 (en) * | 2007-06-08 | 2011-01-13 | Lambris John D | Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation |
EP2550004A4 (en) * | 2010-03-12 | 2014-07-02 | Univ Australian | SUBSTITUTE THERAPY WITH HEPARAN SULFATE |
PL2593113T3 (pl) * | 2010-07-16 | 2019-09-30 | Tx Medic Ab | Terapia komórkowa |
CN102973592A (zh) * | 2012-11-26 | 2013-03-20 | 合肥博太医药生物技术发展有限公司 | 硫酸葡聚糖在制备治疗糖尿病药物中的应用 |
SE537742C2 (sv) * | 2013-05-13 | 2015-10-13 | Tx Medic Ab | Dextransulfat för cellmobilisering |
GB201408233D0 (en) | 2014-05-09 | 2014-06-25 | Austrianova Singapore Pte Ltd | Use of polyanionic composition |
WO2015190989A1 (en) * | 2014-06-12 | 2015-12-17 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
MY178989A (en) * | 2014-06-12 | 2020-10-26 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
SE538503C2 (en) | 2014-11-11 | 2016-08-16 | Tx Medic Ab | New dextran sulfate |
SE539575C2 (en) * | 2015-07-30 | 2017-10-17 | Tx Medic Ab | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
EP3678675A4 (en) * | 2017-09-08 | 2021-07-07 | TX Medic AB | NEW USE OF DEXTRAN SULFATE |
SE544768C2 (en) * | 2021-03-24 | 2022-11-08 | Tx Medic Ab | Combination for treatment of thromboinflammation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0240098A3 (en) * | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
IL88554A0 (en) * | 1988-12-01 | 1989-07-31 | Hadassah Med Org | Compositions containing a compound binding to a heparin receptor |
TW318142B (ko) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
US5464815A (en) | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
CN1178070A (zh) * | 1996-09-27 | 1998-04-08 | 刘春江 | 组织脏器移植用保存溶液·手术等时组织脏器保护溶液 |
CN1057192C (zh) * | 1997-09-10 | 2000-10-11 | 上海长征医院 | 一种配制多器官保存液的方法 |
-
2002
- 2002-11-28 SE SE0203526A patent/SE525461C3/sv not_active IP Right Cessation
-
2003
- 2003-11-26 DE DE60313356T patent/DE60313356T2/de not_active Expired - Lifetime
- 2003-11-26 KR KR1020057009717A patent/KR100828807B1/ko active IP Right Grant
- 2003-11-26 JP JP2004555208A patent/JP4315908B2/ja not_active Expired - Lifetime
- 2003-11-26 AU AU2003302378A patent/AU2003302378B2/en not_active Expired
- 2003-11-26 PL PL376302A patent/PL216067B1/pl unknown
- 2003-11-26 EP EP03811973A patent/EP1567171B1/en not_active Expired - Lifetime
- 2003-11-26 AT AT03811973T patent/ATE359798T1/de active
- 2003-11-26 DK DK03811973T patent/DK1567171T3/da active
- 2003-11-26 CN CNB2003801045438A patent/CN1296051C/zh not_active Expired - Lifetime
- 2003-11-26 US US10/535,876 patent/US8629123B2/en active Active
- 2003-11-26 NZ NZ540744A patent/NZ540744A/en not_active IP Right Cessation
- 2003-11-26 WO PCT/SE2003/001830 patent/WO2004047848A1/en active IP Right Grant
- 2003-11-26 EA EA200500757A patent/EA010409B1/ru not_active IP Right Cessation
- 2003-11-26 SI SI200330809T patent/SI1567171T1/sl unknown
- 2003-11-26 PT PT03811973T patent/PT1567171E/pt unknown
- 2003-11-26 BR BRPI0316666A patent/BRPI0316666B8/pt active IP Right Grant
- 2003-11-26 CA CA2507595A patent/CA2507595C/en not_active Expired - Lifetime
- 2003-11-26 ES ES03811973T patent/ES2285270T3/es not_active Expired - Lifetime
-
2005
- 2005-05-17 IL IL168626A patent/IL168626A/en active IP Right Grant
- 2005-05-17 HR HR20050439A patent/HRP20050439B1/xx not_active IP Right Cessation
- 2005-05-20 ZA ZA200504111A patent/ZA200504111B/en unknown
- 2005-05-25 NO NO20052505A patent/NO326946B1/no not_active IP Right Cessation
- 2005-06-23 IS IS7908A patent/IS2405B/is unknown
-
2006
- 2006-07-03 HK HK06107463A patent/HK1087042A1/xx not_active IP Right Cessation
-
2007
- 2007-07-17 CY CY20071100954T patent/CY1106739T1/el unknown
-
2009
- 2009-03-17 JP JP2009064780A patent/JP4972113B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-11 US US12/685,005 patent/US8906884B2/en active Active
-
2013
- 2013-12-06 US US14/099,493 patent/US9364499B2/en not_active Expired - Lifetime
- 2013-12-06 US US14/099,518 patent/US8901104B2/en not_active Expired - Lifetime
-
2016
- 2016-01-20 US US15/001,380 patent/US10307440B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10307440B2 (en) | Use of dextran sulfate | |
Johansson et al. | Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation | |
Goto et al. | Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets | |
Ozmen et al. | Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation | |
US20060148720A1 (en) | Use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus | |
MXPA05005778A (en) | New use of dextran sulfate | |
RU2315621C2 (ru) | Применение ингибитора или антагониста тканевого фактора |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
N231 | Notification of change of applicant | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130416 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140416 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150420 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160411 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170424 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180412 Year of fee payment: 11 |